Upstream Bio, Inc. (UPB)
Develops new medicines to treat severe lung and breathing diseases
$6.40+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-58.8%
The outlook
UPB is trading near its 52-week low and below both its 50- and 200-day moving averages, reflecting weak near-term momentum. Analyst coverage leans bullish with an average price target roughly 5x the current price, though the overall StockGlow score is bearish. The stock sits at the lower end of its yearly range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +498% vs current price
Analyst price target
~12-month · 8 analysts$38.25average target+497.7% vs now
Now $6.40
Low $8.00High $75.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$348.3M
52-wk high
$33.68
52-wk low
$5.85
50-day avg
$7.23
200-day avg
$16.23
Trailing P/E
—